Table 3.
Can we identify better predictors of risk for recurrence or chemoresistance? |
Can we identify individual variation in gene expression governing drug metabolism which affect both toxicity and efficacy? |
Can we identify genomic patterns which are prognostic or predictive or response to specific drugs or treatment combinations? |
Which patients are best served by neoadjuvant chemotherapy followed by interval cytoreduction? |
How can we best use targeted biologics in combination with initial chemotherapy to improve outcome? |
How can we reduce the toxicity and improve the efficacy of intraperitoneal chemotherapy? |
Does the use of dose-dense (weekly) paclitaxel obviate the benefit of intraperitoneal chemotherapy? |
Should we administer both carboplatin and paclitaxel weekly? |
Does the use of targeted biologics obviate the benefit of intraperitoneal chemotherapy? |
Should consolidation therapy be offered to all patients after initial treatment with debulking surgery and chemotherapy? |